Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Innate Pharma's Sloan Ratio for the quarter that ended in Dec. 2025 was -59.46%.
Warning Sign:
When sloan ratio (-59.39)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.
As of Dec. 2025, Innate Pharma has a Sloan Ratio of -59.46%, indicating earnings are more likely to be made up of accruals.
Innate Pharma (NAS:IPHA) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Dec. 2025, Innate Pharma has a Sloan Ratio of -59.46%, indicating earnings are more likely to be made up of accruals.
Innate Pharma Sloan Ratio % Related Terms
Innate Pharma Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for Innate Pharma's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IPHA vs VRTX, REGN, ALNY: Sloan Ratio % Comparison
For the Biotechnology subindustry, Innate Pharma's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innate Pharma Sloan Ratio % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innate Pharma's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Innate Pharma's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Innate Pharma's Sloan Ratio for the fiscal year that ended in Dec. 2025 is calculated as
For company reported semi-annually, GuruFocus uses latest two semi-annual data as the TTM data.
Innate Pharma's Net Income for the trailing twelve months (TTM) ended in Dec. 2025 was -24.618 (Jun. 2025 ) + -32.591 (Dec. 2025 ) = $-57.21 Mil.
Innate Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was -35.945 (Jun. 2025 ) + -1.633 (Dec. 2025 ) = $-37.58 Mil.
Innate Pharma's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2025 was 8.044 (Jun. 2025 ) + 15.991 (Dec. 2025 ) = $24.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innate Pharma (IPHA) has a Sloan Ratio % of -59.46% as of Dec. 2025. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Innate Pharma and its competitors.
Is Innate Pharma's Sloan Ratio % too high?
Innate Pharma's current Sloan Ratio % is -59.46%. Overall, Innate Pharma has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Innate Pharma's Sloan Ratio % compare to VRTX and REGN?
Innate Pharma's Sloan Ratio % of -59.46% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Biotechnology company?
A good Sloan Ratio % depends on the Biotechnology industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Innate Pharma and its competitors. Innate Pharma's current Sloan Ratio % is -59.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innate Pharma stock overvalued right now?
Based on GuruFocus' analysis, Innate Pharma (IPHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $1.79 — trading 1095% above its estimated fair value. The current Sloan Ratio % is -59.46%. Innate Pharma's overall GF Score™ is 41/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Innate Pharma (IPHA), the current Sloan Ratio % is -59.46% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innate Pharma (IPHA) Overvalued in 2026?
Based on GuruFocus' analysis, Innate Pharma stock appears to be overvalued.
The current stock price of $1.79 is trading 1095% above its estimated GF Value™ of $0.15.
GuruFocus considers Innate Pharma to be Significantly Overvalued.
Key valuation signals for IPHA:
Sloan Ratio %: -59.46%
GF Value™: $0.15 vs. price of $1.79 (1095% above fair value)
No single metric tells the full story. See the IPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
41GF Score
Get the complete analysis for IPHA
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPHA has been successfully added to your 
